| Literature DB >> 30696679 |
Ravi Lokwani1,2, Peter A B Wark1,2,3, Katherine J Baines2, Daniel Barker2, Jodie L Simpson1,2,3.
Abstract
OBJECTIVES: The significance of neutrophilic inflammation in obstructive airway disease remains controversial. Recent studies have demonstrated presence of an active neutrophil population in systemic circulation, featuring hypersegmented morphology, with high oxidative burst and functional plasticity in inflammatory conditions. The aim of this study was to characterise neutrophil subsets in bronchial lavage (BL) of obstructive airway disease participants (asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis) and healthy controls on the basis of nuclear morphology and to assess the association between neutrophil subsets and the clinical parameters of the obstructive airway disease participants.Entities:
Keywords: bronchoscopy; chronic airways disease; immunology
Mesh:
Year: 2019 PMID: 30696679 PMCID: PMC6352776 DOI: 10.1136/bmjopen-2018-024330
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Subsets of neutrophils characterised as per number of lobes in their nucleus. (A) A representative pictomicrograph of bronchial lavage (BL) cytospin of obstructive airway disease participants (×100 original magnification, May-Grünwald Giemsa (MGG) stain) consists of (B) banded neutrophil, (C) normal neutrophil and (D) hypersegmented neutrophil.
Clinical characteristics of participants with bronchiectasis, asthma, COPD and healthy controls
| Bronchiectasis | COPD | Asthma | Healthy | P value | |
| n | 19 | 20 | 39 | 20 | |
| Age | 67.8 (7.1) | 68.8 (10.2) | 64.8 (7.3) | 61.3 (9.7) | 0.024 |
| Males, n (%) | 7 (36.8) | 14 (70.0) | 18 (46.2) | 9 (45.0) | 0.184 |
| Ex-smoker, n (%) | 0 (0.0) | 20 (100.0)*† | 15 (38.5)†‡ | 2 (10.0) | <0.001 |
| Smoking (pack-years) | – | 35.0 (20.0–55.0) | 10.0 (4.0–30.0)‡ | (5.0, 5.0) | 0.007 |
| FEV1% predicted | 91.9 (18.3)‡ | 57.4 (16.9)* | 72.3 (20.1)*† | 98.6 (12.1), n=19 | <0.001 |
| FEV1/FVC (%) | 73.0 (67.0–78.0)‡ | 59.5 (39.0–65.0) | 66.0 (59.0–72.0)*‡ | 75.0 (72.0–80.0)‡, n=19 | <0.001 |
| Taking ICS, n (%) | 0 (0.0) | 8 (40.0) | 37 (94.9)‡ | 0 (0.0) | <0.001 |
| BDP equivalent ICS dose | – | 1700.00 (555.49) | 978.37 (398.70)‡ | – | <0.001 |
| Bacterial pathogen, n (%) | 8 (42.1)* | 8 (40.0)* | 12 (30.8)* | 0 (0) | 0.003 |
| Bronchiectasis severity index | 4 (2.0–7.0), n=18 | – | – | – | – |
| GINA stages of asthma severity, n (%) | |||||
| Intermittent | 1 (2.6) | ||||
| Mild persistent | 6 (15.8) | ||||
| Moderate persistent | 9 (23.7) | ||||
| Severe persistent | 22 (56.4) | ||||
| GOLD stages of COPD severity, n (%) | |||||
| GOLD stage 1 (mild) | 2 (10.0) | ||||
| GOLD stage 2 (moderate) | 11 (55.0) | ||||
| GOLD stage 3 (severe) | 6 (30.0) | ||||
| GOLD stage 4 (very severe) | 1 (5.0) |
Data are presented as mean±SD or median (IQR; Q1–Q3) unless otherwise stated.
BDP equivalent ICS dose is calculated as beclomethasone dipropionate equivalent, where 1 µg of beclomethasone=1 µg budesonide=0.5 µg fluticasone.
*P<0.0125 compared with healthy controls.
†P<0.0125 compared with bronchiectasis.
‡P<0.0125 compared with COPD.
COPD, chronic obstructive pulmonary disease; FEV1, force expiratory volume in 1 s; FVC, forced vital capacity; GINA, Global Initiative for Asthma; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid.
Inflammatory cell count of participants with bronchiectasis, asthma, COPD and healthy controls
| Bronchiectasis | COPD | Asthma | Healthy | P value* | |
| Total cells (×106/mL) | 0.62 (0.19–1.74)† | 0.83 (0.16–1.88)† | 0.16 (0.09–0.34)‡§ | 0.08 (0.05–0.21) | <0.001 |
| Viability (%) | 82.26 (75.00–91.67)† | 87.75 (73.60–92.95)† | 77.78 (62.30–88.00) | 72.22 (50.00–75.00) | 0.005 |
| Neutrophils (%) | 67.50 (41.00–84.25)† | 77.25 (73.00–85.13)† | 58.00 (24.50–72.50)‡ | 28.25 (14.75–63.50) | <0.001 |
| Neutrophils (×104/mL) | 43.20 (5.21–164.43)† | 60.35 (13.31–149.70)† | 8.24 (3.12–25.01)§‡ | 3.18 (1.51–5.03) | <0.001 |
| Eosinophils (%) | 1.00 (0.50–6.50) | 3.75 (1.13–8.88)† | 2.25 (1.00–11.75)† | 1.00 (0.75–1.25) | 0.016 |
| Eosinophils (×104/mL) | 0.75 (0.40–2.76)† | 1.89 (1.03–4.03)† | 0.63 (0.14–3.07)† | 0.09 (0.05–0.23) | <0.001 |
| Macrophages (%) | 18.75 (11.00–34.75) | 15.50 (8.50–20.03)† | 25.00 (9.25–39.25) | 29.25 (17.00–63.12) | 0.025 |
| Macrophages (×104/mL) | 12.40 (5.94–24.42)† | 9.66 (2.91–18.24) | 4.24 (2.00–7.77)§ | 2.10 (1.42–6.43) | 0.002 |
| Lymphocytes (%) | 0.75 (0.00–1.50) | 0.38 (0.00–1.25) | 0.50 (0.00–1.50) | 1.5 (0.25–5.13) | 0.058 |
| Lymphocytes | 0.30 (0.00–1.02) | 0.18 (0.00–0.89) | 0.09 (0.00–0.37) | 0.18 (0.05–0.42) | 0.459 |
| Columnar epithelial cells (%) | 1.75 (0.75–10.50) | 0.25 (0.00–2.50)† | 4.50 (1.50–10.75)‡ | 9.50 (4.88–23.63) | <0.001 |
| Columnar epithelial cells (×104/mL) | 1.99 (0.48–2.67)‡ | 0.28 (0.00–0.59)† | 1.00 (0.35–1.98)‡ | 0.88 (0.38–2.38) | <0.001 |
Data are presented as median (IQR; Q1–Q3) unless otherwise stated.
*Kruskal-Wallis test.
†P<0.0125 compared with healthy controls.
‡P<0.0125 compared with COPD.
§P<0.0125 compared with bronchiectasis.
COPD, chronic obstructive pulmonary disease.
Figure 2Neutrophil subset number (A–C) and neutrophil subset proportion (D–F) in bronchial lavage (BL) of participants with bronchiectasis, chronic obstructive pulmonary disease (COPD), asthma and healthy controls. The line in dot plots of each group represents the median. ^P<0.0125 compared with healthy controls; *P<0.0125 compared with asthma; and #P<0.0125 compared with COPD, as per Kruskal-Wallis test.
Figure 3Scatterplot of hypersegmented neutrophil proportion versus FEV1% predicted (A) and FEV1/FVC (B) in bronchial lavage (BL) of obstructive airway disease participants. COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
Figure 4(A) Scatterplot of hypersegmented neutrophil proportion versus eosinophil proportion, (B) viability of total cells in bronchial lavage (BL) of chronic obstructive pulmonary disease (COPD) participants.
Figure 5Neutrophil subsets proportion (A–C) and neutrophil subsets number (D–F) in bronchial lavage of eosinophilic chronic obstructive pulmonary disease (E-COPD) and non-eosinophilic COPD (NE-COPD) participants. The line in dot plots of each group represents the median and the p value in each graph is an outcome of Wilcoxon rank-sum test.